Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

October 31, 2014

Conditions
Preterm Delivery
Interventions
DRUG

17-alpha-hydroxy-progesterone caproate, Makena®

Intramuscular (IM) injection of 17P,Makena® (250mg) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.

DRUG

Castor Oil (Placebo)

IM injections of Placebo (castor oil) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.

Trial Locations (15)

36617

University of South Alabama Medical Center, Mobile

40202

Norton Kosair Children's Hospital, Louisville

49503

Spectrum Health Hospital, Grand Rapids

64111

Saint Luke's Hospital, Kansas City, Kansas City

80110

Swedish Medical Center, Denver

80218

Presbyterian/St Luke's Hospital, Denver

85006

Banner Good Samaritan Hospital, Phoenix

85202

Desert Good Samaritan Hospital, Mesa

85712

Tucson Medical Center, Tucson

89109

Sunrise Medical Center, Las Vegas

95124

Good Samaritan Hospital, San Jose

95128

OConnor Hospital, San Jose

90801-1428

Long Beach Memorial Medical Center, Long Beach

45267-0526

University of Cincinnati, Cincinnati

98122-4307

Swedish Medical Center, Seattle

Sponsors
All Listed Sponsors
lead

Obstetrix Medical Group

INDUSTRY

NCT01119963 - Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM) | Biotech Hunter | Biotech Hunter